Trastuzumab deruxtecan, an antibody-drug conjugate, demonstrated encouraging antitumor activity during a phase 2 trial that evaluated patients with HER2+ metastatic BC, including 24 patients with BM [48]. Here, ERBB2 is linked to breast cancer.